Bristol-Myers Squibb

November 7, 2016November 7, 2016

Bristol-Myers to Present Data on New Immunotherapy Combo to Treat Lymphoma

News

Bristol-Myers Squibb will present new data on the potential of its immunotherapy agent Opdivo (nivolumab) in combination with Yervoy (ipilimumab), and combinations with or without Opdivo of other investigational immunotherapies, to treat various cancers. ... Read more

October 27, 2016October 27, 2016

New Report Supports Opdivo for Relapsed Hodgkin’s Lymphoma Patients

News

Bristol-Myers Squibb recently presented data supporting the use of Opdivo (nivolumab) in a subgroup of patients with classical Hodgkin’s lymphoma who had undergone a prior stem cell transplant and treatment with ... Read more

October 18, 2016

EMA Panel Recommends Opdivo’s European Approval for Classical Hodgkin’s Lymphoma

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of classical Hodgkin’s lymphoma (cHL) in patients who relapsed or progressed ... Read more